Overexpression of the novel member of the BCL2 gene family, BCL2L12, is associated with the disease outcome in patients with acute myeloid leukemia

Clinical Biochemistry

Volumn 45, Issue 16-17, 2012, Pages 1362-1367

  Thomadaki, Hellinida ^a   Floros, Konstantinos V ^a   Pavlovic, Sonja ^b   Tosic, Natasa ^b   Gourgiotis, Dimitrios ^a   Colovic, Milica ^b   Scorilas, Andreas ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

AML; Apoptosis; BCL2 family; Prognosis; Real time PCR

Indexed keywords

BCL 2L12 PROTEIN; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; MESSENGER RNA; PROTEIN BCL 2; RNA; STEM CELL FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; APOPTOSIS; ARTICLE; BLOOD; CHI SQUARE TEST; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FISHER EXACT TEST; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PARAMETERS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RELAPSE; RNA ISOLATION; SPLENOMEGALY; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CASE-CONTROL STUDIES; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPATOMEGALY; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUSCLE PROTEINS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS C-BCL-2; SPLENOMEGALY; TREATMENT OUTCOME; UP-REGULATION; YOUNG ADULT;

EID: 84868303971     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2012.06.012     Document Type: Article

References (47)

1. Lowenberg B., Downing J.R., Burnett A. Acute myeloid leukemia. N Engl J Med 1999, 341:1051-1062.
2. Advani A.S., Rodriguez C., Jin T., Jawde R.A., Saber W., Baz R., et al. Increased C-kit intensity is a poor prognostic factor for progression-free and overall survival in patients with newly diagnosed AML. Leuk Res 2008, 32:913-918.
3. Moore J.O., George S.L., Dodge R.K., Amrein P.C., Powell B.L., Kolitz J.E., et al. Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222. Blood 2005, 105:3420-3427.
4. Kohler T., Schill C., Deininger M.W., Krahl R., Borchert S., Hasenclever D., et al. High Bad and Bax mRNA expression correlate with negative outcome in acute myeloid leukemia (AML). Leukemia 2002, 16:22-29.
5. Scorilas A., Kyriakopoulou L., Yousef G.M., Ashworth L.K., Kwamie A., Diamandis E.P. Molecular cloning, physical mapping, and expression analysis of a novel gene, BCL2L12, encoding a proline-rich protein with a highly conserved BH2 domain of the Bcl-2 family. Genomics 2001, 72:217-221.
6. Kontos C.K., Scorilas A. Molecular cloning of novel alternatively spliced variants of BCL2L12, a new member of the BCL2 gene family, and their expression analysis in cancer cells. Gene 2012, 10.1016/j.gene.2012.04.084.
7. Stegh A.H., Kesari S., Mahoney J.E., Jenq H.T., Forloney K.L., Protopopov A., et al. Bcl2L12-mediated inhibition of effector caspase-3 and caspase-7 via distinct mechanisms in glioblastoma. Proc Natl Acad Sci U S A 2008, 105:10703-10708.
8. Yang J., Hong Y., Wang W., Wu W., Chi Y., Zong H., et al. HSP70 protects BCL2L12 and BCL2L12A from N-terminal ubiquitination-mediated proteasomal degradation. FEBS Lett 2009, 583:1409-1414.
9. Zhang H., Gao S., De Geyter C. A natural antisense transcript, BOKAS, regulates the pro-apoptotic activity of human Bok. Int J Oncol 2009, 34:1135-1138.
10. Mathioudaki K., Scorilas A., Papadokostopoulou A., Xynopoulos D., Arnogianaki N., Agnanti N., et al. Expression analysis of BCL2L12, a new member of apoptosis-related genes, in colon cancer. Biol Chem 2004, 385:779-783.
11. Kontos C.K., Papadopoulos I.N., Scorilas A. Quantitative expression analysis and prognostic significance of the novel apoptosis-related gene BCL2L12 in colon cancer. Biol Chem 2008, 389:1467-1475.
12. Talieri M., Diamandis E.P., Katsaros N., Gourgiotis D., Scorilas A. Expression of BCL2L12, a new member of apoptosis-related genes, in breast tumors. Thromb Haemost 2003, 89:1081-1088.
13. Thomadaki H., Talieri M., Scorilas A. Prognostic value of the apoptosis related genes BCL2 and BCL2L12 in breast cancer. Cancer Lett 2007, 247:48-55.
14. Florou D., Papadopoulos I.N., Scorilas A. Molecular analysis and prognostic impact of the novel apoptotic gene BCL2L12 in gastric cancer. Biochem Biophys Res Commun 2010, 391:214-218.
15. Stegh A.H., Kim H., Bachoo R.M., Forloney K.L., Zhang J., Schulze H., et al. Bcl2L12 inhibits post-mitochondrial apoptosis signaling in glioblastoma. Genes Dev 2007, 21:98-111.
16. Fendri A., Kontos C.K., Khabir A., Mokdad-Gargouri R., Scorilas A. BCL2L12 is a novel biomarker for the prediction of short-term relapse in nasopharyngeal carcinoma. Mol Med 2011, 17:163-171.
17. Geomela P.A., Kontos C.K., Yiotakis I., Scorilas A. Quantitative expression analysis of the apoptosis-related gene, BCL2L12, in head and neck squamous cell carcinoma. J Oral Pathol Med 2012, 10.1111/j.1600-0714.2012.01190.x.
18. Papageorgiou S.G., Kontos C.K., Pappa V., Thomadaki H., Kontsioti F., Dervenoulas J., et al. The novel member of the BCL2 gene family, BCL2L12, is substantially elevated in chronic lymphocytic leukemia patients, supporting its value as a significant biomarker. Oncologist 2011, 16:1280-1291.
19. Floros K.V., Talieri M., Scorilas A. Topotecan and methotrexate alter expression of the apoptosis-related genes BCL2, FAS and BCL2L12 in leukemic HL-60 cells. Biol Chem 2006, 387:1629-1633.
20. Floros K.V., Thomadaki H., Lallas G., Katsaros N., Talieri M., Scorilas A. Cisplatin-induced apoptosis in HL-60 human promyelocytic leukemia cells: differential expression of BCL2 and novel apoptosis-related gene BCL2L12. Ann N Y Acad Sci 2003, 1010:153-158.
21. Grimwade D., Walker H., Oliver F., Wheatley K., Harrison C., Harrison G., et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998, 92:2322-2333.
22. Kontos C.K., Papadopoulos I.N., Fragoulis E.G., Scorilas A. Quantitative expression analysis and prognostic significance of L-DOPA decarboxylase in colorectal adenocarcinoma. Br J Cancer 2010, 102:1384-1390.
23. Mrozek K., Marcucci G., Paschka P., Whitman S.P., Bloomfield C.D. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?. Blood 2007, 109:431-448.
24. Estey E., Dohner H. Acute myeloid leukaemia. Lancet 2006, 368:1894-1907.
25. Nakao M., Yokota S., Iwai T., Kaneko H., Horiike S., Kashima K., et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 1996, 10:1911-1918.
26. Schichman S.A., Caligiuri M.A., Strout M.P., Carter S.L., Gu Y., Canaani E., et al. ALL-1 tandem duplication in acute myeloid leukemia with a normal karyotype involves homologous recombination between Alu elements. Cancer Res 1994, 54:4277-4280.
27. King-Underwood L., Pritchard-Jones K. Wilms' tumor (WT1) gene mutations occur mainly in acute myeloid leukemia and may confer drug resistance. Blood 1998, 91:2961-2968.
28. Pabst T., Mueller B.U., Zhang P., Radomska H.S., Narravula S., Schnittger S., et al. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. Nat Genet 2001, 27:263-270.
29. Wouters B.J., Lowenberg B., Delwel R. A decade of genome-wide gene expression profiling in acute myeloid leukemia: flashback and prospects. Blood 2009, 113:291-298.
30. Wilson C.S., Davidson G.S., Martin S.B., Andries E., Potter J., Harvey R., et al. Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction. Blood 2006, 108:685-696.
31. Baldus C.D., Thiede C., Soucek S., Bloomfield C.D., Thiel E., Ehninger G. BAALC expression and FLT3 internal tandem duplication mutations in acute myeloid leukemia patients with normal cytogenetics: prognostic implications. J Clin Oncol 2006, 24:790-797.
32. Heuser M., Beutel G., Krauter J., Dohner K., von Neuhoff N., Schlegelberger B., et al. High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics. Blood 2006, 108:3898-3905.
33. Marcucci G., Baldus C.D., Ruppert A.S., Radmacher M.D., Mrozek K., Whitman S.P., et al. Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study. J Clin Oncol 2005, 23:9234-9242.
34. Sakamoto Y., Mariya Y., Sasaki S., Teshiromori R., Oshikiri T., Segawa M., et al. WT1 mRNA level in peripheral blood is a sensitive biomarker for monitoring minimal residual disease in acute myeloid leukemia. Tohoku J Exp Med 2009, 219:169-176.
35. Del Poeta G., Venditti A., Del Principe M.I., Maurillo L., Buccisano F., Tamburini A., et al. Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML). Blood 2003, 101:2125-2131.
36. Kornblau S.M., Vu H.T., Ruvolo P., Estrov Z., O'Brien S., Cortes J., et al. BAX and PKCalpha modulate the prognostic impact of BCL2 expression in acute myelogenous leukemia. Clin Cancer Res 2000, 6:1401-1409.
37. Estrov Z., Thall P.F., Talpaz M., Estey E.H., Kantarjian H.M., Andreeff M., et al. Caspase 2 and caspase 3 protein levels as predictors of survival in acute myelogenous leukemia. Blood 1998, 92:3090-3097.
38. Campos L., Rouault J.P., Sabido O., Oriol P., Roubi N., Vasselon C., et al. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 1993, 81:3091-3096.
39. Lauria F., Raspadori D., Rondelli D., Ventura M.A., Fiacchini M., Visani G., et al. High bcl-2 expression in acute myeloid leukemia cells correlates with CD34 positivity and complete remission rate. Leukemia 1997, 11:2075-2078.
40. Osato N., Suzuki Y., Ikeo K., Gojobori T. Transcriptional interferences in cis natural antisense transcripts of humans and mice. Genetics 2007, 176:1299-1306.
41. Fendri A., Kontos C.K., Khabir A., Mokdad-Gargouri R., Ardavanis A., Scorilas A. Quantitative analysis of BCL2 mRNA expression in nasopharyngeal carcinoma: an unfavorable and independent prognostic factor. Tumour Biol 2010, 31:391-399.
42. Uhlmann E.J., Subramanian T., Vater C.A., Lutz R., Chinnadurai G. A potent cell death activity associated with transient high level expression of BCL-2. J Biol Chem 1998, 273:17926-17932.
43. Hammond P.W., Alpin J., Rise C.E., Wright M., Kreider B.L. In vitro selection and characterization of Bcl-X(L)-binding proteins from a mix of tissue-specific mRNA display libraries. J Biol Chem 2001, 276:20898-20906.
44. Stegh A.H., Chin L., Louis D.N., DePinho R.A. What drives intense apoptosis resistance and propensity for necrosis in glioblastoma? A role for Bcl2L12 as a multifunctional cell death regulator. Cell Cycle 2008, 7:2833-2839.
45. Stegh A.H., Brennan C., Mahoney J.A., Forloney K.L., Jenq H.T., Luciano J.P., et al. Glioma oncoprotein Bcl2L12 inhibits the p53 tumor suppressor. Genes Dev 2010, 24:2194-2204.
46. Kornblau S.M., Thall P.F., Estrov Z., Walterscheid M., Patel S., Theriault A., et al. The prognostic impact of BCL2 protein expression in acute myelogenous leukemia varies with cytogenetics. Clin Cancer Res 1999, 5:1758-1766.
47. Cohen G.M. Caspases: the executioners of apoptosis. Biochem J 1997, 326(Pt 1):1-16.